{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:46:21Z","timestamp":1791161181037,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.antiviral.2015.04.002","type":"journal-article","created":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T03:58:15Z","timestamp":1428638295000},"page":"132-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["The hepatitis B virus ribonuclease H as a drug target"],"prefix":"10.1016","volume":"118","author":[{"given":"John E.","family":"Tavis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lomonosova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.04.002_b0005","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.1128\/JVI.76.12.6356-6363.2002","article-title":"Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication","volume":"76","author":"Addison","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0010","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1073\/pnas.1112389109","article-title":"Probing chelation motifs in HIV integrase inhibitors","volume":"109","author":"Agrawal","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2015.04.002_b0015","doi-asserted-by":"crossref","first-page":"e1003784","DOI":"10.1371\/journal.ppat.1003784","article-title":"Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?","volume":"9","author":"Bertoletti","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.04.002_b0020","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1021\/jm8007085","article-title":"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain","volume":"51","author":"Billamboz","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2015.04.002_b0025","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1021\/jm1014692","article-title":"Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and\/or the HIV-1 reverse transcriptase ribonuclease H domain: discovery of a novel selective inhibitor of the ribonuclease H function","volume":"54","author":"Billamboz","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2015.04.002_b0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2013.01.006","article-title":"Chronic hepatitis B: What should be the goal for new therapies?","volume":"98","author":"Block","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.04.002_b0035","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/nar\/gki268","article-title":"Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones","volume":"33","author":"Budihas","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2015.04.002_b0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.antiviral.2014.05.007","article-title":"Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity","volume":"108","author":"Cai","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.04.002_b0045","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.00473-12","article-title":"Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation","volume":"56","author":"Cai","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.04.002_b0050","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2174\/0929867321666140120121158","article-title":"Recent progress in the research of small molecule HIV-1 RNase H inhibitors","volume":"21","author":"Cao","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.antiviral.2015.04.002_b0055","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1128\/JVI.64.11.5553-5558.1990","article-title":"Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase","volume":"64","author":"Chang","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0060","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1128\/JVI.70.9.6151-6156.1996","article-title":"Amino acids essential for RNAse H activity of hepadnaviruses are also required for efficient elongation of minus-strand DNA","volume":"70","author":"Chen","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0065","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jmv.22014","article-title":"Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents","volume":"83","author":"Cheng","year":"2011","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0166-3542(02)00023-2","article-title":"Expression of the active human and duck hepatitis B virus polymerases in heterologous system of Pichia methanolica","volume":"55","author":"Choi","year":"2002","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.04.002_b0075","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1021\/jm2000757","article-title":"Synthesis, activity, and structural analysis of novel alpha-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H","volume":"54","author":"Chung","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2015.04.002_b0080","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2893.2010.01321.x","article-title":"Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy","volume":"18","author":"Coffin","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2015.04.002_b0085","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1517\/14728214.2011.646260","article-title":"Emerging pipeline drugs for hepatitis B infection","volume":"16","author":"Cox","year":"2011","journal-title":"Expert. Opin. Emerg. Drugs"},{"key":"10.1016\/j.antiviral.2015.04.002_b0090","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-2006-939760","article-title":"Small animal model systems for studying hepatitis B virus replication and pathogenesis","volume":"26","author":"Dandri","year":"2006","journal-title":"Semin. Liver Dis."},{"issue":"Suppl 1","key":"10.1016\/j.antiviral.2015.04.002_b0095","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S1386-6532(05)80011-3","article-title":"Animal models for the study of HBV replication and its variants","volume":"34","author":"Dandri","year":"2005","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0100","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1128\/AAC.49.12.4884-4894.2005","article-title":"Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones","volume":"49","author":"Didierjean","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.04.002_b0105","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1002\/hep.22920","article-title":"Benefits and risks of nucleoside analog therapy for hepatitis B","volume":"49","author":"Dienstag","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.04.002_b0110","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1126\/science.7801124","article-title":"Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases","volume":"266","author":"Dyda","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.04.002_b0115","doi-asserted-by":"crossref","first-page":"11244","DOI":"10.1073\/pnas.200139397","article-title":"HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase","volume":"97","author":"Espeseth","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2015.04.002_b0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3851\/IMP2690","article-title":"Past and future. Current drugs targeting HIV-1 integrase and reverse transcriptase-associated ribonuclease H activity: single and dual active site inhibitors","volume":"23","author":"Esposito","year":"2014","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.antiviral.2015.04.002_b0125","series-title":"Fields Virology","first-page":"2107","article-title":"HIVs and their replication","author":"Freed","year":"2007"},{"key":"10.1016\/j.antiviral.2015.04.002_b0130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000360938","article-title":"Host factor-targeted hepatitis B virus therapies","volume":"57","author":"Gehring","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.antiviral.2015.04.002_b0135","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1128\/JVI.70.7.4269-4274.1996","article-title":"Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis","volume":"70","author":"Gerelsaikhan","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0140","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1053\/j.gastro.2007.02.039","article-title":"Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B","volume":"132","author":"Ghany","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.04.002_b0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2180-1-12","article-title":"Evidence that the RNAseH activity of the duck hepatitis B virus is unable to act on exogenous substrates","volume":"1","author":"Gong","year":"2001","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0150","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.1128\/JVI.01123-07","article-title":"Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation","volume":"81","author":"Guo","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0155","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature08784","article-title":"Retroviral intasome assembly and inhibition of DNA strand transfer","volume":"464","author":"Hare","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.04.002_b0160","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1038\/emboj.2012.118","article-title":"3\u2019-Processing and strand transfer catalysed by retroviral integrase in crystallo","volume":"31","author":"Hare","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2015.04.002_b0165","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1128\/JVI.03000-13","article-title":"Ultradeep pyrosequencing and molecular modeling identify key structural features of hepatitis B virus RNase H, a putative target for antiviral intervention","volume":"88","author":"Hayer","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0170","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.pharmtox.011008.145553","article-title":"Emerging pharmacology: inhibitors of human immunodeficiency virus integration","volume":"49","author":"Hazuda","year":"2009","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0175","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1021\/cb600303y","article-title":"HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site","volume":"1","author":"Himmel","year":"2006","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0180","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1016\/j.bmcl.2014.09.037","article-title":"Inhibition of the ANT(2\u2019\u2019)-Ia resistance enzyme and rescue of aminoglycoside antibiotic activity by synthetic alpha-hydroxytropolones","volume":"24","author":"Hirsch","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2015.04.002_b0185","series-title":"Nulceases","first-page":"341","article-title":"Ribonuclease H","author":"Hostomsky","year":"1993"},{"key":"10.1016\/j.antiviral.2015.04.002_b0190","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.antiviral.2013.06.007","article-title":"Beta-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity","volume":"99","author":"Hu","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.04.002_b0195","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/347306a0","article-title":"Three-dimensional structure of ribonuclease H from E. coli","volume":"347","author":"Katayanagi","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.04.002_b0200","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-5793(89)80110-3","article-title":"Prediction of terminal protein and ribonuclease H domains in the gene P product of hepadnaviruses","volume":"243","author":"Khudyakov","year":"1989","journal-title":"FEBS Lett."},{"key":"10.1016\/j.antiviral.2015.04.002_b0205","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1021\/jm900597q","article-title":"RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information","volume":"52","author":"Kirschberg","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2015.04.002_b0210","first-page":"183","article-title":"Uncovering the complexities of retroviral ribonuclease H reveals its potential as a therapeutic target","volume":"4","author":"Klarmann","year":"2002","journal-title":"AIDS Rev."},{"key":"10.1016\/j.antiviral.2015.04.002_b0215","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1093\/nar\/gkg881","article-title":"Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors","volume":"31","author":"Klumpp","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2015.04.002_b0220","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2174\/138161206776873653","article-title":"Recent progress in the design of small molecule inhibitors of HIV RNase H","volume":"12","author":"Klumpp","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.antiviral.2015.04.002_b0225","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrgastro.2011.33","article-title":"Hepatitis B therapy","volume":"8","author":"Kwon","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0230","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0969-2126(00)00179-9","article-title":"Crystal structure of archaeal RNase HII: a homologue of human major RNase H","volume":"8","author":"Lai","year":"2000","journal-title":"Structure"},{"issue":"Suppl 1","key":"10.1016\/j.antiviral.2015.04.002_b0235","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1386-6532(05)00384-7","article-title":"Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention","volume":"34","author":"Lavanchy","year":"2005","journal-title":"Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology"},{"key":"10.1016\/j.antiviral.2015.04.002_b0240","doi-asserted-by":"crossref","first-page":"40850","DOI":"10.1074\/jbc.R112.389056","article-title":"Human immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise","volume":"287","author":"Le Grice","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2015.04.002_b0245","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1006\/bbrc.1997.6467","article-title":"RNase H activity of human hepatitis B virus polymerase expressed in Escherichia coli","volume":"233","author":"Lee","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2015.04.002_b0250","first-page":"S1359","article-title":"Targeting HIV-1 integrase with strand transfer inhibitors","volume":"6","author":"Li","year":"2014","journal-title":"Drug Discov. Today Dec."},{"issue":"Suppl 1","key":"10.1016\/j.antiviral.2015.04.002_b0255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/liv.12057","article-title":"Impact of therapy on the outcome of chronic hepatitis B","volume":"33","author":"Liaw","year":"2013","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"key":"10.1016\/j.antiviral.2015.04.002_b0260","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0076-6879(01)41168-2","article-title":"Human RNases H","volume":"341","author":"Lima","year":"2001","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0265","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1128\/AAC.04617-14","article-title":"Hydroxylated tropolones inhibit hepatitis b virus replication by blocking the viral ribonuclease H activity","volume":"59","author":"Lu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.04.002_b0270","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3851\/IMP1496","article-title":"Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy","volume":"15","author":"Lui","year":"2010","journal-title":"Antivir. Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2015.04.002_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/liv.12422","article-title":"Viral hepatitis: impressive advances but still a long way to eradication of the disease","volume":"34","author":"Marcellin","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2015.04.002_b0280","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1039\/c4md00055b","article-title":"The biology and synthesis of alpha-hydroxytropolones","volume":"5","author":"Meck","year":"2014","journal-title":"MedChemComm"},{"key":"10.1016\/j.antiviral.2015.04.002_b0285","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1021\/ol302892g","article-title":"An oxidopyrylium cyclization\/ring-opening route to polysubstituted alpha-hydroxytropolones","volume":"14","author":"Meck","year":"2012","journal-title":"Org. Lett."},{"key":"10.1016\/j.antiviral.2015.04.002_b0290","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/07853890.2014.883169","article-title":"Integrase strand transfer inhibitors in the management of HIV-positive individuals","volume":"46","author":"Mesplede","year":"2014","journal-title":"Ann. Med."},{"key":"10.1016\/j.antiviral.2015.04.002_b0295","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ajg.2009.726","article-title":"Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop","volume":"105","author":"Monto","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0300","doi-asserted-by":"crossref","first-page":"9392","DOI":"10.1128\/JVI.71.12.9392-9399.1997","article-title":"Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus","volume":"71","author":"Moraleda","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0305","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/embor.2008.256","article-title":"Retroviral integrase superfamily: the structural perspective","volume":"10","author":"Nowotny","year":"2009","journal-title":"EMBO Rep."},{"key":"10.1016\/j.antiviral.2015.04.002_b0310","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.cell.2005.04.024","article-title":"Crystal structures of RNase H bound to an RNA\/DNA hybrid: substrate specificity and metal-dependent catalysis","volume":"121","author":"Nowotny","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2015.04.002_b0315","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/sj.emboj.7601076","article-title":"Stepwise analyses of metal ions in RNase H catalysis from substrate destabilization to product release","volume":"25","author":"Nowotny","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2015.04.002_b0320","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.pep.2007.04.005","article-title":"Optimized expression from a synthetic gene of an untagged RNase H domain of human hepatitis B virus polymerase which is enzymatically active","volume":"55","author":"Potenza","year":"2007","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.antiviral.2015.04.002_b0325","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1128\/JVI.64.2.613-620.1990","article-title":"Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity","volume":"64","author":"Radziwill","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0330","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3748\/wjg.v13.i1.14","article-title":"Hepatitis B virus taxonomy and hepatitis B virus genotypes","volume":"13","author":"Schaefer","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0335","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/aid.1988.4.ix","article-title":"Amino acid sequence similarity between retroviral and E. coli RNase H and hepadnaviral gene products","volume":"4","author":"Schodel","year":"1988","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.antiviral.2015.04.002_b0345","series-title":"Fields Virology","first-page":"2185","article-title":"Hepadnaviruses","author":"Seeger","year":"2013"},{"key":"10.1016\/j.antiviral.2015.04.002_b0350","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-150-2-200901200-00100","article-title":"National institutes of health consensus development conference statement: management of hepatitis B","volume":"150","author":"Sorrell","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2015.04.002_b0355","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.1128\/JVI.00353-10","article-title":"Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors","volume":"84","author":"Su","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0360","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0092-8674(82)90157-X","article-title":"Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate","volume":"29","author":"Summers","year":"1982","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2015.04.002_b0365","doi-asserted-by":"crossref","unstructured":"Tavis, J.E., Badtke, M.P., 2009. Hepadnaviral Genomic Replication, in: Cameron, C.E., G\u00f6tte, M., Raney, K.D. (Eds.), Viral Genome Replication. Springer Science+Business Media, LLC, New York, pp. 129\u2013143.","DOI":"10.1007\/b135974_7"},{"key":"10.1016\/j.antiviral.2015.04.002_b0370","doi-asserted-by":"crossref","first-page":"e1003125","DOI":"10.1371\/journal.ppat.1003125","article-title":"The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes","volume":"9","author":"Tavis","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.04.002_b0375","doi-asserted-by":"crossref","first-page":"7451","DOI":"10.1128\/AAC.03875-14","article-title":"Inhibitors of nucleotidyl transferase superfamily enzymes suppress herpes simplex virus replication","volume":"58","author":"Tavis","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.04.002_b0380","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","article-title":"Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","volume":"51","author":"van Bommel","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.04.002_b0385","doi-asserted-by":"crossref","first-page":"32617","DOI":"10.1074\/jbc.271.51.32617","article-title":"Expression, purification, and characterization of an active RNase H domain of the hepatitis B viral polymerase","volume":"271","author":"Wei","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2015.04.002_b0390","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1128\/JVI.70.9.6455-6458.1996","article-title":"Relationship between viral DNA synthesis and virion envelopment in hepatitis B viruses","volume":"70","author":"Wei","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.04.002_b0395","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.04.002_b0400","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1016\/j.bmcl.2010.08.135","article-title":"Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold","volume":"20","author":"Williams","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2015.04.002_b0405","doi-asserted-by":"crossref","first-page":"11707","DOI":"10.1021\/jo401617r","article-title":"Triflic acid-mediated rearrangements of 3-methoxy-8-oxabicyclo[3.2.1]octa-3,6-dien-2-ones: synthesis of methoxytropolones and furans","volume":"78","author":"Williams","year":"2013","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2015.04.002_b0410","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/135965350601100704","article-title":"One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels","volume":"11","author":"Wong","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2015.04.002_b0415","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2010.06.042","article-title":"Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses","volume":"139","author":"Woo","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.04.002_b0420","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0969-2126(01)00142-3","article-title":"Recombining the structures of HIV integrase, RuvC and RNase H","volume":"3","author":"Yang","year":"1995","journal-title":"Structure"},{"key":"10.1016\/j.antiviral.2015.04.002_b0425","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.2174\/092986707782023253","article-title":"Plant troponoids: chemistry, biological activity, and biosynthesis","volume":"14","author":"Zhao","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.antiviral.2015.04.002_b0430","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1128\/JVI.75.1.311-322.2001","article-title":"Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis","volume":"75","author":"Zhu","year":"2001","journal-title":"J. Virol."},{"issue":"Suppl 1","key":"10.1016\/j.antiviral.2015.04.002_b0435","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1478-3231.2010.02399.x","article-title":"Hepatitis B virus resistance to antiviral drugs: where are we going?","volume":"31","author":"Zoulim","year":"2011","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2015.04.002_b0440","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215000820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215000820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T20:05:20Z","timestamp":1651694720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215000820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":87,"alternative-id":["S0166354215000820"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.04.002","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The hepatitis B virus ribonuclease H as a drug target","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}